HIV InfectionsNCT05363865
Digital Community to Improve Health in Rural Areas
A study testing Virtual Community Intervention in people with HIV Infections and Hepatitis C Virus Infection, run by University of Pennsylvania at 1 site in United States.
Trial summary
The study is a cluster randomized controlled trial developed in counties located in Appalachia and the Midwest. We will prioritize counties from states with high risk for HIV and HCV infection associated with injection drug use. Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- HIV Infections, Hepatitis C Virus Infection
- What is being tested?
- Virtual Community Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 511 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Jun 2023to 31 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Lives in target zip codes
- Half not using illicit substances (not including marijuana) currently or in the past
- Half using illicit substances (not including marijuana) currently or in the past
Who cannot join
- Under the age of 18
- Not in target zip codes
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Pennsylvania
Philadelphia, Pennsylvania, 19103
About this study
Official title: Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia
The study is a cluster randomized controlled trial developed in counties located in Appalachia and the Midwest. We will prioritize counties from states with high risk for HIV and HCV infection associated with injection drug use.
Read the detailed description
The study will randomize clusters with groups of participants to an intervention or a standard of care condition.
- Conditions
- HIV Infections, Hepatitis C Virus Infection
- Being tested
- Virtual Community Intervention, Standard of Care
- Medical subject headings
- HIV Infections, Hepatitis C
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Community InterventionBehavioural
Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
Standard of CareBehavioural
health websites and county information provided to participants
| Study group | Role | What they receive |
|---|---|---|
| Virtual Community Intervention | Experimental | Participants will participate in an online community with structured sessions as well as the ability to communicate freely with others. Receives: Behavioral: Virtual Community Intervention |
| Standard of Care | Active comparator | Participants will be exposed to what's disseminated within their communities Receives: Behavioral: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Test HIV
Self-request of HIV test and confirmation of completion.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Test HCV
Self-request of HCV test and confirmation of completion.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Know HIV Status
Self-report of HIV status understanding.
Binary (I tested positive for HIV; I tested negative for HIV.)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Know HCV Status
Self-report of HCV status understanding.
Binary (I tested positive for HCV; I tested negative for HCV.)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Receive HIV Treatment
Self-report of HIV treatment reception.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Receive HCV Treatment
Self-report of HCV treatment reception.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Receive Over-the-Counter Narcan
Request to receive over-the-counter Narcan, depending on the ability to distribute Narcan in the state of residence.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use syringe services (e.g., exchange)
Self-report of using a syringe service program.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Disinfect injection equipment
Self-report of injection tool cleaning prior to use.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
New Social Connections
Self-report of new social connections made with others in the community.
Continuous (Numeric)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Renewed Social Connections
Self-report of reconnecting with previously distant community members.
Continuous (Numeric)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Contributions to town, neighborhoods, and community
Self-report of community engagement and betterment through acts of service or kindness.
Scale (Not at all; A little; Somewhat; A lot; A great deal)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Discovering services or groups
Self-report of newly discovered social services or groups in their communities.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Joining groups, organizations, or activities
Self-report of newly joined groups, organizations, or activities in the community.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Encouraging others to test for HIV/HCV
Self-report of instances where individuals suggest or encourage HIV/HCV testing.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Encouraging others to treat substance use disorder or HIV/HCV
Self-report of instances where individuals suggest or encourage others to be treated for substance use disorder, HIV, or HCV.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Discuss substance use issues with others
Self-report of instances where individual discusses substance use issues with other members of their community.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Secondary outcomes (29)
Use PrEP
Self-report of PrEP use.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use a condom during sex
Self-report of condom use during sex.
Scale (Never; Sometimes; Almost always; Always)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support for another with a health issue
Self-report of supporting others as they attend to a health issue.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support somebody who is presently struggling with substance use disorder
Self-report of providing support for someone with SUD.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support somebody who has had struggles with substance use disorder
Self-report of providing support for someone with a past SUD.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support somebody who has a family member who has a substance use disorder
Self-report of providing support for the relative of someone with SUD.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Refrain from using hurtful language to refer to people with substance use disorder
Self-report of hurtful or stigmatizing language towards people with SUD.
Scale (Never; Sometimes; Almost always; Always)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Refrain from using hurtful language to refer to people from other groups (e.g., religious)
Self-report of hurtful or stigmatizing language towards people of other groups.
Scale (Never; Sometimes; Almost always; Always)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Intention to intervene when someone uses hurtful language
Self-report of behavioral intentions to prevent or intervene in hurtful or stigmatizing language.
Scale (Never; Sometimes; Almost always; Always)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
See a mental health professional if there are mental health concerns including substance use
Self-report of seeking professional help with mental health concerns.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend a 12-step group (if using substances or in recovery)
Self-report of 12-step group attendance for people who use drugs or are in recovery.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend another abstinence-based program (if using substances or in recovery)
Self-report of abstinence-based program attendance for people who use drugs or are in recovery (not 12-step group or religious-based).
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend a substance use treatment program that uses medications (if using substances or in recovery)
Self-report of medication-assisted recovery program attendance for people who use drugs or are in recovery.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend a religious-based substance use group (if using substances or in recovery)
Self-report of religious-based substance use group attendance.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Receive COVID-19 vaccine(s) as currently required (measure past and last shot)
Self-report of received COVID-19 vaccine shots, with most recent shot date and number of shots.
Binary (Yes/No) Date (YMD)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Take a flu shot during the most recent season
Self-report of received influenza vaccine shots, with most recent shot date.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Carry Naloxone
Self-report of frequency that an individual has Naloxone on their person.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use Naloxone on someone
Self-report of instances where Naloxone was used by the individual to address an overdose or suspected overdose.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Has someone administered Naloxone on you?
Self-report of another using Naloxone on the individual.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Test for COVID-19
Self-report of COVID-19 testing.
Binary (Yes/No) Continuous (Numerical)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Test for M-pox
Self-report of M-pox testing received.
Binary (Yes/No)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Drink alcohol frequency
Self-report of frequency of alcohol consumption, number of drinks, and drunkenness.
Scale (Never; A few times but not in the past year Once a month; A few times a month Once a week; A few times a week Once a day; More than once a day) Scale (Never; A few times but not in the past year Once a month; A few times a month Once a week; A few times a week Once a day; More than once a day)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use substance without a prescription or more than prescribed
Self-report of substance use, not including proper use of prescription drugs.
Scale (Never; Tried it one or more times; Once a month or less often; 2-4 times a month; 2-3 times a week; 4 times a week or more)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Injection drug use
Self-report of injection drug use, not including proper use of prescription drugs.
Binary (Yes/No) Scale (Not at all; A few times; A few times a week; Everyday)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use someone else's syringe
Self-report of sharing needles with another person.
Continuous (Numerical)
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Complete Narcan training
Completion of requested Narcan Training.
Binary (Yes/No)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Requesting safe-injection supplies
Request for wound-care kits for injection sites and/or syringe cleaning kits.
Measured: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support for medication assisted treatment (MAT)
Self-report of support for MAT.
Scale: (Not at all; A little; Somewhat; A lot; A great deal)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support for therapeutic programs to reduce drug addiction
Self-report of support for therapeutic programs to reduce drug addiction.
Scale: (Not at all; A little; Somewhat; A lot; A great deal)
Measured: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2022
- Study start12 Jun 2023
- Primary completion31 Aug 2025
- Study completion31 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- Clusters will be randomized to either the intervention or the standard of care.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 511 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dolores Albarracin, PhD, Principal investigator, Univ. of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05363865
- Sponsor's protocol ID
- 390234
- Status last verified
- Mar 2026
- First submitted
- 21 Apr 2022
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia
- ClinicalTrials.gov ID
- NCT05363865
- Acronym / sponsor ID
- 390234
- Conditions
- HIV Infections, Hepatitis C Virus Infection
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 511 participants (actual)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Study start
- 12 Jun 2023 (actual)
- Primary completion
- 31 Aug 2025 (actual)
- Study completion
- 31 Aug 2025 (actual)
- First posted
- 6 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is a cluster randomized controlled trial developed in counties located in Appalachia and the Midwest. We will prioritize counties from states with high risk for HIV and HCV infection associated with injection drug use.
Detailed description
The study will randomize clusters with groups of participants to an intervention or a standard of care condition.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Clusters will be randomized to either the intervention or the standard of care.
| Arm | Type | Receives |
|---|---|---|
| Virtual Community Intervention | Experimental | Behavioral: Virtual Community InterventionParticipants will participate in an online community with structured sessions as well as the ability to communicate freely with others. |
| Standard of Care | Active comparator | Behavioral: Standard of CareParticipants will be exposed to what's disseminated within their communities |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Lives in target zip codes
- Half not using illicit substances (not including marijuana) currently or in the past
- Half using illicit substances (not including marijuana) currently or in the past
Key exclusion criteria (2 listed)
- Under the age of 18
- Not in target zip codes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual Community InterventionModules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems | Behavioural | Virtual Community Intervention |
| Standard of Carehealth websites and county information provided to participants | Behavioural | Standard of Care |
Primary outcome
Test HIV
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-request of HIV test and confirmation of completion. Binary (Yes/No)
Test HCV
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-request of HCV test and confirmation of completion. Binary (Yes/No)
Know HIV Status
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of HIV status understanding. Binary (I tested positive for HIV; I tested negative for HIV.)
Know HCV Status
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of HCV status understanding. Binary (I tested positive for HCV; I tested negative for HCV.)
Receive HIV Treatment
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of HIV treatment reception. Binary (Yes/No)
Receive HCV Treatment
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of HCV treatment reception. Binary (Yes/No)
Receive Over-the-Counter Narcan
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Request to receive over-the-counter Narcan, depending on the ability to distribute Narcan in the state of residence. Binary (Yes/No)
Use syringe services (e.g., exchange)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of using a syringe service program. Binary (Yes/No)
Disinfect injection equipment
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of injection tool cleaning prior to use. Binary (Yes/No)
New Social Connections
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of new social connections made with others in the community. Continuous (Numeric)
Renewed Social Connections
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of reconnecting with previously distant community members. Continuous (Numeric)
Contributions to town, neighborhoods, and community
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of community engagement and betterment through acts of service or kindness. Scale (Not at all; A little; Somewhat; A lot; A great deal)
Discovering services or groups
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of newly discovered social services or groups in their communities. Binary (Yes/No)
Joining groups, organizations, or activities
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of newly joined groups, organizations, or activities in the community. Binary (Yes/No)
Encouraging others to test for HIV/HCV
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of instances where individuals suggest or encourage HIV/HCV testing. Binary (Yes/No)
Encouraging others to treat substance use disorder or HIV/HCV
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of instances where individuals suggest or encourage others to be treated for substance use disorder, HIV, or HCV. Binary (Yes/No)
Discuss substance use issues with others
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Self-report of instances where individual discusses substance use issues with other members of their community. Binary (Yes/No)
29 secondary outcomes
Use PrEP
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use a condom during sex
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support for another with a health issue
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support somebody who is presently struggling with substance use disorder
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support somebody who has had struggles with substance use disorder
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support somebody who has a family member who has a substance use disorder
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Refrain from using hurtful language to refer to people with substance use disorder
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Refrain from using hurtful language to refer to people from other groups (e.g., religious)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Intention to intervene when someone uses hurtful language
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
See a mental health professional if there are mental health concerns including substance use
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend a 12-step group (if using substances or in recovery)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend another abstinence-based program (if using substances or in recovery)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend a substance use treatment program that uses medications (if using substances or in recovery)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Attend a religious-based substance use group (if using substances or in recovery)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Receive COVID-19 vaccine(s) as currently required (measure past and last shot)
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Take a flu shot during the most recent season
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Carry Naloxone
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use Naloxone on someone
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Has someone administered Naloxone on you?
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Test for COVID-19
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Test for M-pox
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Drink alcohol frequency
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use substance without a prescription or more than prescribed
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Injection drug use
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Use someone else's syringe
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Complete Narcan training
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Requesting safe-injection supplies
Time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support for medication assisted treatment (MAT)
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Support for therapeutic programs to reduce drug addiction
Time frame: Baseline, Session 2 (~2 weeks, Experimental Group Only), Session 3 (~3 weeks, Experimental Group Only), Immediate Follow-Up (3 Weeks), 3 months, 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for HIV Infections
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dolores Albarracin, PhD principal investigator
Univ. of Pennsylvania
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Community Intervention in people with HIV Infections and Hepatitis C Virus Infection, run by University of Pennsylvania at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Test HIV (time frame: Baseline, Immediate Follow-Up (3 Weeks), 3 months, 6 months). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.